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Abstract 25 
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In the field of live viral vaccines production, there is an unmet need for in vitro tests complying 26 
a 3R approach (Refine, Replace and Reduce the use of animal experimentation) to replace the 27 
post-licensing safety tests currently assayed in animals. Here, we performed a pilot study 28 
evaluating whether virulence of rabies virus, RABV, can be forecast by an in vitro test of neurite 29 
outgrowth. The rationale to use neurite outgrowth as a read-out for this test is based on the 30 
salient property of the cytoplasmic domain of the G-protein (Cyto-G) of virulent RABV strains 31 
- not of attenuated RABV strains - to stimulate neurite outgrowth in vitro. We observed that 32 
neurite elongation triggered by the Cyto-Gs encoded by different RABV field isolates correlate 33 
with the distinct virulence scores obtained in a mouse model of experimental rabies. Our results 34 
cast the idea that it could be feasible to predict RABV virulence by testing the in vitro property 35 
of a RABV strain to promote neurite outgrowth without the use of animal experimentation. 36 
 37 
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1. Introduction 42 
Vaccines are invaluable tools to prevent diseases and to increase the live expectancy of humans. 43 
Some vaccines are prepared with live non-virulent microbes. Their safe use requires that they 44 
are devoid of mutants which have acquired virulent features back. Before release for human 45 
immunization, batches of live viral vaccines such as those of Yellow Fever, Measles or 46 
Polioviruses, have to be tested for the absence of neurovirulence. At the moment, this post-lic47 
ensing safety testing is performed in animals. Ethical considerations questioning the use of 48 
animals, monkeys in particular, in research strongly advocate for alternative methods. The 3R 49 
approach (Reduce, Refine, Replace the use of animals) is now clearly a priority for the world 50 
health authorities and a real challenge for scientists to stimulate their ingenuity on alternative 51 
in vitro tests that do not require animal experimentation [1]. A cellular test, which could 52 
amplify and make detectable phenotypic trait linked to neurovirulence is highly desirable. 53 
Nevertheless, because neurovirulence is a polygenic trait often not completely elucidated, the 54 
design of relevant in vitro test may not be an easy task. 55 
Here, we performed a pilot study to bring a proof of concept to validate the relevance of such 56 
an approach. To this purpose, the neurotropic rabies virus (RABV) was chosen as a model since 57 
some mechanisms controlling RABV pathogenicity start to be unravelled. The virulent RABV 58 
strain CVS, referred as CVS-NIV, which invades the nervous system of the mouse and on being 59 
injected in the hind limb causes a fatal encephalitis [2], whereas the non-neurotropic strain 60 
ERA-NIV does not [3, 4] and triggers striking distinct features (attenuation, apoptosis and a 61 
robust antibody induction). Surprisingly enough for such a lethal neurotropic virus, CVS-NIV 62 
promotes neuron survival and triggers neurite elongation (neurite outgrowth), whereas ERA-63 
NIV does not share these properties and instead induces the death of the infected neurons. 64 
Amongst the five RABV proteins, the glycoprotein (G-protein), an integral trans-membrane 65 
protein, has been identified as playing a critical role in the fate of viral properties [3, 5-12]. 66 
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These features are controlled not only by the ectodomain of the G-protein, but also by the 67 
cytoplasmic domain, Cyto-G which was found to control the fate of the infected cell (cellular 68 
death or survival) through the interaction with some cellular partners [13, 14]. Commitment of 69 
RABV-infected neurons towards cellular survival or death is under the control of the carboxyl 70 
terminus (C-terminus) of Cyto-G forming a PDZ Binding Motif (PBM), which interacts with 71 
the PDZ domain (Post synaptic density protein, Drosophila disc large tumor suppressor, and 72 
Zonula occludens-1 protein domain) of a select group of cellular partners [14-17]. PDZ domains 73 
are protein-protein interacting domains and play a central role in cell signaling by favoring 74 
spatial contact between enzymes and their substrates, and more generally by assembling and/or 75 
regulating protein networks [18, 19]. Remarkably, in a model of strictly isogenic recombinant 76 
RABVs the introduction of a single point mutation in the C-terminus of Cyto-G (COOH Cyto-77 
G) of the CVS-NIV switched neurosurvival to neuronal death. This single change is sufficient 78 
to induce the loss of virulence markers (neurite outgrowth, increase in AKT phosphorylation 79 
and protection against apoptosis) and the acquisition of markers of attenuation (increase in the 80 
number of cellular partners of the Cyto-G, induction of apoptosis). This change also modifies 81 
pathogenicity in a mouse model of RABV encephalitis [14]. With this background, it can be 82 
expected that the expression of the Cyto-G CVS-NIV or ERA-NIV alone and in the absence of 83 
any other RABV components may be sufficient to reproduce the in vitro neurosurvival and 84 
attenuation features of RABVs. The delivery of Cyto-Gs could be obtained for example by 85 
infecting the cells with recombinant lentiviral vectors. If this was the case, it could be possible 86 
to predict virulence of a RABV strain by performing an in vitro test of neurite outgrowth.  87 
In this study we designed such an in vitro test, and challenged this test by assaying whether in 88 
vitro virulence features of three representative South African RABV isolates (a canid, a 89 
mongoose and a spill over corresponding to a dog infected by a mongoose RABV biotype) and 90 
whose Cyto-Gs were distinct by a few mutations correlate with the virulence of the strains as 91 
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previously determined in an experimental mouse model of rabies (Seo, W et al. companion 92 
paper). Despite the limited number of strains used for the correlate, this pilot study gave 93 
promising results suggesting that virulence, at least in the case of RABV infection, might be 94 
forecast by performing in vitro tests.  95 
 96 
2. Material and Methods  97 
2.1 Cells 98 
Human embryonic kidney cells HEK 293-T were grown at 37 °C with 5% CO2 in Dulbecco’s 99 
Modified Eagle Medium with Glutamax-1 supplemented with 10% fetal calf serum (FCS), 100 
penicillin (10,000 IU/ml) and streptomycin (10 mg/ml). Neuroscreen-1 (Cellomics), derived 101 
from rat pheochromocytoma were grown in RPMI 1640 supplemented with 10% horse serum, 102 
5% FCS, 200 mM glutamine, penicillin (10,000 IU/ml) and streptomycin (10 mg/ml). 103 
 104 
2.2 Construction and Recovery of Recombinant lentivirus 105 
Chimeric G-protein constructs were generated by using the plasmid with the deleted 106 
ectodomain that resulted in delta EC. The mutant clones were generated by amino acid 107 
substitutions using QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent 108 
Technologies) with mutagenic primers (Eurogentec Co). The primer sets for site-directed 109 
mutagenesis of the 3 constructs are shown below. 110 
Canid 
Canid 1 5’TGGGAATCATACAAGAGTGGGGGTGAGACCAGACTGTGAGGCCAAG3’ 
Canid 2 3’ACCCTTAGTATGTTCTCACCCCCACTCTGGTCTGACACTCCGGTTC5’ 
Mongoose 
Mong 1 5’TGGGAATCATACAAGAATGGGGAGGAGACCAGAATGTGAGGCCAAG3’ 
Mong 2 3’ACCCTTAGTATGTTCTTACCCCTCCTCTGGTCTTACACTCCGGTTC5’ 
Spill over 
Spill over 1 5’TGGGAATCATACAAGAATGGGGGTGAGACCAGAATGTGAGGCCAAG3’ 
Spill over 2 3’ACCCTTAGTATGTTCTTACCCCCACTCTGGTCTTACACTCCGGTTC5’ 
ERA ERA 1 5’TGGGAATCACACAAGAGTGGGGGTGAGACCAGACTGTGAGGCCAAG3’ 
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ERA 2 3’ACCCTTAGTGTGTTCTCACCCCCACTCTGGTCTGACACTCCGGTTC5’ 
  111 
Then, the chimeric transgenes were cloned in the lentivirus vector by using the pLenti6.3/V5-112 
TOPO® TA Cloning® Kits (Invitrogen). A total number of 5×106 HEK 293-T cells were grown 113 
overnight to 80% confluence in 10 cm diameter Cell+ dishes (Sarstedt). The transfection was 114 
conducted using the calcium phosphate method. HIV vectors were prepared as previously 115 
described by co-transfecting HEK 293-T cells with a four-plasmid system including the above 116 
plasmids carrying the genes of interest, the pMDLg/pRRE, the pRSV-Rev packaging plasmids 117 
and the VSV-G envelope protein expression plasmid (pMDG) [20]. HIV Gag protein p24 118 
measured in 48 hours supernatants by the enzyme-linked immunosorbent assay (HIV p24 119 
ELISA, Perkin Elmer). The infectivity of each stock was monitored on Neuroscreen-1 cells 120 
before use. A dose of 33 ng of p24 was needed to infect 5×104 Neuroscreen-1 cells. One hundred 121 
percent of infection was achieved 48-hour-post infection in these conditions. This dose was 122 
determined by using an eGFP (enhanced green fluorescent protein) expressing lentivirus 123 
included in each experiment to check the infectivity. Real-time relative qPCR (RT-qPCR) was 124 
further conducted and the level of 18S rRNA expression was used to as a house keeping gene. 125 
 126 
2.3 Western Blotting and Immunocytochemistry 127 
Lentivirus and non-infected cells were lysed with RIPA buffer (Sigma) supplemented with 128 
anti-protease and anti-phosphatase cocktails (Roche Life Science) and stored at -20 °C. Cell 129 
lysates were electrophoresed on a 4-20% gradient polyacrylamide gel (Pierce Biotechnology) 130 
and blotted on PVDF membranes (Hybond-P, GE HealthCare). The membranes were incubated 131 
with a customized polyclonal rabbit antibody directed against the Cyto-G (Proteogenix) 132 
followed by an incubation with a secondary antibody coupled to horseradish peroxidase 133 
(Jackson Immuno Research). Signals were revealed with SuperSignal® West Femto Substrate 134 
(Pierce Biotechnology), acquired and analyzed with chemiluminescence imaging system 135 
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(G:Box, Syngene). 136 
For immunocytochemistry Neuroscreen-1 cells were infected for 48 hours with recombinant 137 
lentiviruses (20 ng of p24/well) on coverslips in a 24-well plate. Fixed cells were incubated 138 
with anti Cyto-G polyclonal customized rabbit antibodies (Proteogenix) followed by goat-anti 139 
rabbit labeled with Alexa 488 (Molecular Probe). Nuclei were stained with Hoescht 333420 140 
and analyzed with a Leica confocal microscope Zeiss LSM 510. 141 
 142 
2.4 Neurite Outgrowth Assay 143 
A total number of 5×104 Neuroscreen-1 cells were seeded in 24 well poly-D-lysine-coated 144 
tissue culture dishes (Cell Bind, Corning). After 6-hour-incubation with 200 ng of neuronal 145 
growth factor (NGF), recombinant lentiviral stock containing 60 ng of p24 was added and cells 146 
were further cultivated for 72 hours. Cells were fixed and stained with crystal violet solution to 147 
visualize neurite processes. Cell images were captured (3 field/well, 10 wells/group) with a 148 
phase contrast Leica microscope and analyzed with ImageJ 1.44p, Neuron J plug-in. 149 
 150 
2.5 Statistical Analysis 151 
Student's t-test (P<0.05 was considered significant) was undertaken using GraphPad Prism 152 
version 6.0 program. 153 
 154 
3. Results 155 
3.1 Construction and expression of Cyto-Gs  156 
The commitment of RABV-infected neurons toward death (i.e. ERA-NIV) or survival (i.e. 157 
CVS-NIV) is controlled by the Cyto-G and the PBM located at the COOH terminus of the Cyto-158 
G protein in particular [14].  We wanted here to assay whether Cyto-G expressed alone, in the 159 
absence of any other RABV elements, retains the neurosurvival features. We chose to construct 160 
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a Cyto-G of the CVS-NIV (44 amino acids long) and 4 chimeric Cyto-Gs replacing the 12 161 
original amino acid residues of CVS-NIV Cyto-G by the 12 amino acids of the COOH terminal 162 
of ERA-NIV Cyto-G or those of the three South African RABV (Canid, Mongoose and Spill 163 
over) (Fig. 1A). The reason to engraft 12 COOH amino acids and not the 4 COOH amino acids, 164 
which is the most common length of a PBM, is motivated by the results of nuclear magnetic 165 
resonance (NMR) and X-rays studies indicating that up to 12 amino acids of RABV Cyto-G 166 
could be involved in the formation of the PBM/PDZ complexes [15, 16]. The Cyto-G constructs 167 
included the transmembrane domain (TM) of the G-protein and G,K amino acids of ectodomain 168 
proximal to the TM as well as the entire signal peptide 19 amino acid long (Fig. 1A) to allow 169 
sorting and trafficking of the Cyto-Gs from the endoplasmic reticulum. A negative control, 170 
consisting in the G-CVS-NIV deleted of the last 4 amino acids, G-CVS-NIV, was also 171 
constructed. Lentiviruses were chosen as a mean to express the Cyto-Gs in Neuroscreen-1 cells. 172 
The mRNA transcription levels of lentivirus constructs were evaluated by relative RT-qPCR 173 
(Fig. 1B) and ERA-NIV and Spill over constructs exhibited the lowest value, however, the 174 
mRNA expression of CVS-NIV showed the highest value. Interestingly, the G-canid and G-175 
mongoose constructs displayed similar mRNA transcriptional levels. These data suggested that 176 
point mutations in the nucleotide sequence may slightly modify the intrinsic stability of the 177 
mRNA transcripts. Nevertheless, when the Cyto-G protein expression was assayed by 178 
immunoblotting (Fig. 1C) and immunocytochemistry (Fig. 1D), all chimeric constructs 179 
exhibited high levels of protein expression. To note, in contrast to CVS-NIV infected cells, in 180 
which the full length G-protein is localized both in the cytoplasm and at the cytoplasmic 181 
membrane (data not shown), or in cells infected by a lentiviral vector expressing the entire G-182 
protein only [16], the Cyto-Gs were mainly localized in the cytoplasm of the cells. This may 183 
suggest that RABV G-protein trafficking was modified by the absence of the ectodomain (but 184 
two amino acids) of the RABV G-protein. 185 
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 186 
3.2 The Cyto-G of CVS-NIV expressed out of a RABV context is sufficient to trigger neurite 187 
outgrowth. 188 
 The capacity of Cyto-Gs to trigger neurite outgrowth in a PBM-dependent manner has been 189 
previously assayed in human neuroblastoma SH-SY5Y cells infected with isogenic 190 
recombinant RABVs [14]. Here, we tested whether the neurite outgrowth triggered by CVS-191 
NIV Cyto-G could also be observed after the Cyto-Gs have been delivered in the cells by a 192 
lentiviral vector. For this assay the human neuroblastoma SH-SY5Y cell line was replaced by 193 
rat Neuroscreen-1, which compared to human neuroblastoma, are less prone to cellular 194 
aggregation, allowing for an easier evaluation of neurite outgrowth in individual cells [21].  195 
 Neuroscreen-1 cells were either non-infected or infected with the recombinant lentiviruses G-196 
CVS-NIV, G-ERA-NIV, G-CVS-NIV- and the mean neurite length was measured 72-hour-197 
post infection (Fig. 2 and table 2). The CVS-NIV construct triggered significantly higher neurite 198 
outgrowth compared to non-infected group and to G-CVS-NIV-or ERA-NIV constructs 199 
(mean length of 420 µm for CVS-NIV versus 200 µm for the other conditions: non-infected or 200 
G-CVS-NIV- or ERA-NIV), indicating that the increased neurite outgrowth triggered by 201 
CVS-NIV Cyto-G could also be observed after Cyto-Gs has been delivered in rat Neuroscreen-202 
1 cells by a lentiviral vector. The lentiviral vector Cyto-G CVS-NIV- triggered a mean neurite 203 
outgrowth similar to those observed in non-infected cells (left panel in Fig. 2C and table 2). 204 
This observation rules out the possibilities that the lentiviral vector has an effect on neurite 205 
outgrowth besides the specific contribution of the Cyto-G-PBM. 206 
These data established that Cyto-G of CVS-NIV has an intrinsic property to trigger neurite 207 
outgrowth even in the absence of G ectodomain or any other viral components. In this test, the 208 
property of Cyto-G of ERA-NIV or of CVS-NIV-Δ (to not stimulate neurite outgrowth) is also 209 
maintained. Thus, the in vitro test of neurite outgrowth using lentivirus for the ERA or CVS 210 
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Cyto-G delivery reproduce the in vitro neurosurvival and attenuation features triggered by the 211 
complete viruses.  212 
 213 
3.3 Comparison of neurite outgrowth induced by the three South African chimeric constructs in 214 
a recombinant lentivirus system 215 
Using these experimental conditions, the capacity of the three South African chimeric Cyto-216 
Gs to trigger neurite outgrowth was compared to the positive (CVS-NIV) and negative (ERA-217 
NIV) Cyto-G constructs. The G-canid chimeric construct showed the highest level of neurite 218 
outgrowth, in the same range as those triggered by the positive control CVS-NIV, whereas G-219 
spill over and G-mongoose Cyto-G constructs triggered relatively lower levels of neurite 220 
outgrowth, but significantly higher than those induced by chimeric G-ERA-NIV (Fig. 2 and 221 
Table 2 for statistical analysis). G-spill over and G-mongoose triggered similar levels of neurite 222 
outgrowth. The difference between the efficiency of G-spill over and G-mongoose constructs 223 
compared to G-canid construct was not due to a reduced G-protein expression because no 224 
significant differences in the level of expression of G constructs were observed after lentiviral 225 
vector delivery (Fig. 2D, left plot: 4.99, 5.04 and 5.20 x 107AU for Canid, Mongoose and Spill-226 
over G constructs expression respectively). Moreover, as shown in Fig. 2D, when the level of 227 
expression of G constructs (G-CVS-NIV, G-CVS-NIVΔ, G-ERA-NIV and G-canid chimera, G-228 
mongoose chimera, G-spill over-chimera) was plotted with the neurite outgrowth scores, it 229 
appeared there was no obvious correlation between the expression of G construct an neurite 230 
outgrowth values. For example (Fig. 2D, left panel), the neurite outgrowth score of the G-231 
mongoose chimera construct was lower compared to those of G-canid chimera, despite a similar 232 
G expression, it is the same result for G-CVS-NIV (highest neurite score, lowest level of G 233 
expression) and G-CVS-NIVΔ (Lowest neurite score, highest level of G expression) as shown 234 
on Fig 2D, right panel. This confirm previous observations establishing that RABV virulence 235 
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is not correlated to the G-protein expression level, but in fact to the genetic nature of the 236 
delivered G-protein [14, 22]. 237 
To conclude, in an attempt to predict relative virulence of the three South African RABVs, 238 
the in cellular assay of neurite outgrowth triggered by the C-terminus of the Cyto-Gs allowed 239 
us to propose that the G-canid construct exhibited virulent traits of CVS-NIV constructs, 240 
whereas both the spill over and the mongoose constructs showed less virulent traits. These in 241 
vitro findings correlate with the virulence of the three RABV strains as previously established 242 
in an experimental mouse model of rabies (Seo W et al, companion paper). 243 
 244 
4. Discussion 245 
In the vaccine field, there is an unmet need for a post licensing safety test capable to predict 246 
neurovirulence of live viral vaccine samples without the use of in vivo animal models. Safety 247 
tests for live vaccine (for example Yellow fever vaccines) require that vaccine samples are 248 
injected in monkeys whose brains are collected and checked for the absence of anatomo-249 
pathology signs. The rationale of such a test is that neurotoxicity signs will reveal the presence 250 
of neurotoxic mutants which have appeared in the process of production and can cause vaccine-251 
associated neuropathology. The growth of a pathogenic viral population within the nervous 252 
system may result into the acquisition and then fixation of few genomic mutations that confer 253 
neurovirulence. 254 
Viruses are masters for manipulating the proliferation or death of the infected cells of a host, 255 
mainly by interfering with crucial endogenous interactions. RABV pathogenicity relies on its 256 
potential to keep the infected neurons alive, thereby allowing efficient viral transmission from 257 
one neuron to the next order neuron, from the site of infection up to the brain stem and finally 258 
to be secreted by the salivary glands [13]. It has been shown that virulent laboratory RABV 259 
strains such as CVS-NIV trigger survival of the infected neurons [3]. In contrast, the attenuated 260 
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laboratory RABV strain, ERA-NIV, induces neuronal death. The neurosurvival phenotype is 261 
characterized by an increase of the neurite length of human neuroblastoma cells and by the 262 
activation of the neurosurvival Pi3k-Akt signaling pathway [14]. By using isogenic 263 
recombinant RABVs, we previously demonstrated these features are controlled by the 264 
cytoplasmic domain of the G protein, and in particular by the C-terminus PBM. 265 
Here, we showed that the expression of the last 12 C-terminus of G-CVS-NIV in 266 
Neuroscreen-1 cells assumes the neurosurvival properties of CVS-NIV, whereas the expression 267 
of the last 12 COOH terminus of G-ERA-NIV does not have such an effect. This indicates that 268 
the neurosurvival properties of CVS-NIV and ERA-NIV could be described in vitro without the 269 
need of manipulating RABV isolates, by simply studying the characteristics of the C-terminus 270 
of one of the RABV proteins. 271 
Then we challenged the test by assaying the C-terminus properties of three South African 272 
RABV strains. We found that the C-terminus of the canid RABV isolate G-protein exhibited a 273 
survival phenotype (neurite outgrowth), whereas the C-terminus of mongoose or spill over G-274 
protein did not. In this frame, it can be expected that canid strains are more virulent than spill 275 
over and mongoose strains. This forecast fits with the in vivo data since virulence of the RABV 276 
strains was in this order of magnitude: Canid and CVS virulence superior to those of mongoose 277 
and spill over RABV strains (Seo et al., companion paper). These results indicated that the 278 
virulence of these three wildlife RABV strains can be predicted by monitoring neurite 279 
outgrowth in vitro and again without the need of manipulating RABV isolates and infecting 280 
animals. 281 
It was previously established by comparing in a recombinant RABV system the role of G-282 
protein of two laboratory strains CVS-NIV and ERA-NIV that the control of neurosurvival or 283 
death relies on the nature of the PBM. In particular, a mutation resulting in a single amino acid 284 
change [glutamine (Q) to glutamic acid (E) at -3] in the PBM was sufficient to switch the fate 285 
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of the infected cells and the neurite outgrowth suggesting that expression of ETRLCOOH in this 286 
genetic context (Fig. 1A) was a marker of attenuation [14]. However, ETRL COOH alone might 287 
not be a signature of attenuation whatever the genetic context is. Indeed, the virulent canid 288 
strain stimulates neurite outgrowth while Cyto-G terminates by ETRL. It is likely that another 289 
mutation such as the replacement of the histidine (H) of CVS by Tyrosine (Y) at position -8 290 
modifies the pattern. In that case, the combination of Y at -8 with -ETRLCOOH should trigger a 291 
virulent property. This is strongly supported by the observation that this sequence combination 292 
(H at -8 and ETRL COOH) is expressed by the G-protein of several other virulent strains including 293 
the CVS-AJ506997 (GenBank Acc. AJ506997.1). The possibility that Y at -8 contributes to the 294 
interaction of Cyto-Gs with the PDZ of cellular partners is strongly supported by structural 295 
studies resolving the complex formed by the PBM of RABV Cyto-Gs and the PDZ of the 296 
cellular partner [16]. 297 
A PBM classically corresponds to a stretch of 4 amino acids, allowing the insertion of the 298 
peptide into the groove formed by two beta sheets of the PDZ. Nevertheless, in the case of 299 
RABV Cyto-G structural studies indicated that more than 4 amino acids of the C-terminus of 300 
Cyto-Gs contribute to the formation of the PBM-PDZ complex and that the surface of 301 
interaction recruited the 12 amino acids COOH end [16]. 302 
The reasons why the replacement of H by Y changes the phenotype driven by the PBM 303 
terminated by ETRL are still unclear. A change in the nature of the cellular partners is unlikely 304 
because the 12 COOH termini Cyto-Gs of the three South African strains have highly similar 305 
patterns of reactivity, when assayed in a PDZ array including 220 distinct human PDZs (Renaud 306 
Vincentelli, Nicolas Wolff and Gilles Travé, personal communication). It has been shown in 307 
other models, that phosphorylation of residues in the PBM can modulate PBM/PDZ interactions 308 
[23, 24]. Thus, we may hypothesize that the swap H/Y at -8 modifies the phosphorylation status 309 
of the Cyto-Gs. Such a hypothesis deserves complete studies determining at first whether Cyto-310 
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Gs terminated by ETRL COOH and expressing Y at -8 instead of H have distinct patterns of 311 
phosphorylation and second, whether phosphorylation status of the PBM modulates the pattern 312 
of interaction with cellular partners. 313 
The main conclusion of this discrepancy is that it is not sufficient to look at the primary amino 314 
acid sequence of Cyto-Gs to forecast virulence of a RABV strain, emphasizing that other tests 315 
including in vitro tests are mandatory to answer this question. 316 
In an attempt to replace animal use in post-licensing safety tests for live viral vaccines, this 317 
pilot study using RABV as a model, proposes that virulence of a RABV strain might be 318 
predicted by simply assaying in vitro the capacity of the COOH terminus of its G-protein to 319 
trigger neurite outgrowth. We showed that it is feasible to predict virulence of a RABV strain 320 
by using appropriate in vitro tests. To note, none of the RABV vaccine for human belongs to 321 
the category of live viral vaccines, all of RABV vaccines for human use contain inactivated 322 
viral particles. Thus, the test we set up has no ambition to be substituted to safety tests currently 323 
in use to check for inactivation or potency of rabies vaccines. We hope such a study may pave 324 
the way to propose new tests replacing the injection of animals in the post-licensing safety tests 325 
currently requested for several live viral vaccines for human use. 326 
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Legends  405 
Fig. 1. Construction and characterization of lentivectors expressing RABV Cyto-G 406 
constructs. A) Construction of chimera Cyto-Gs and sequences of the 12 COOH amino acids 407 
of the G protein of CVS-NIV, ERA-NIV and the three South Africa RABV strains (Canid, 408 
Mongoose or Spill-over, the latter resulting from the infection of a dog by a mongoose RABV 409 
strain). Chimera Cyto-Gs (44aa) are formed by the Signal peptide, SP, G and K amino acids 410 
from the ectodomain, transmembrane domain, TM, (19 aa), the Constant domain (32aa) from 411 
the CVS-NIV Cyto-G and a variable insert (12aa) corresponding to the 12 COOH terminus aa 412 
of Cyto-Gs of the different RABV strains distinct by 5 mutations (bold). B) Relative 413 
abundance of G mRNA transcription levels in a recombinant lentivirus system obtained by 414 
relative RT-qPCR (The left and right panels represent independent experiments). C) 415 
Expression of the chimera Cyto-Gs (7.4 kDa) in Neurocreen-1 cells after a 48h-infection with 416 
lentivirus expressing either G-ERA-NIV, G-canid chimera, G-mongoose chimera, G-spill-417 
over chimera or G-CVS-NIV (N.I. is for non-infected). M= molecular weight marker. D) 418 
Expression of Cyto-G constructs in 48h transduced (CVS, ERA, DOG, MON =Mongoose or 419 
SO =Spill Over) or non-treated (NEG). Neuroscreen- 1 cells was monitored by confocal 420 
microscopy using RABV specific Cyto-G polyclonal antibody (green). The nucleus is in blue 421 
after Hoescht 33342 staining. Scale bars : 10 µm. 422 
 423 
Fig. 2 Neurite outgrowth. Cultures of Neuroscreen cultivated for 72 hours after lentivirus 424 
transduction. Cells were fixed and stained with crystal violet solution to visualize neurite 425 
processes. A) Representative fields of cultures. B) Neurite outgrowth drawing (ImageJ 1.44p, 426 
Neuron J plug-in) of representative N.I (non-infected) or 72h-lentivirus transduced 427 
Neuroscreen-1 cells. C) Comparison of mean neurite outgrowth (µm) triggered in N.I or cells 428 
expressing either: G-CVS NIV and G-CVS NIV (left panel) or N.I., G CVS-NIV, G-canid, 429 
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G-mongoose, G-spill-over or G-ERA-NIV chimera (right panel). The data are representative 430 
of duplicate independent experiments. Neurites were counted in 55 fields for each condition 431 
(with at least one neurite per field). See table 2 for Statistical significance. D) Absence of 432 
correlation between G constructs and neurite outgrowth experimental values. The level of 433 
expression of the G constructs and the mean neurite length obtained are not correlated each 434 
other, whatever the nature of the chimera construct (the left and right panels represent 435 
independent experiments). 436 
